Cempta ( CEMP ) won a small measure of vindication earlier this month when a FDA advisory panel narrowly voted to recommend agency approval for its controversial antibiotic. That small measure is disappearing. Earlier today, Cowen’s Ritu Baral became the latest in a string of analysts to downgrade the drug maker over the past month, cutting her rating to market perform from outperform. The reason: a “significant lack of clarity on the path forward for both lead product solithromycin as well as Cempra as a company.”